It has been estimated that there are almost five million American men and women over 50 years of age who experience dry-eye symptoms. This conservative estimate will correspondingly rise due to the anticipated growth of the 'baby boomer' age group, as well as the growth of refractive surgery. Numerous studies have reported not only a loss in quality of life but also a loss in work-related performance due to the visual detriment caused by dry-eye syndrome (DES), also known as dysfunctional tear syndrome (DTS).
It has been estimated that there are almost five million American men and women over 50 years of age who experience dry-eye symptoms. This conservative estimate will correspondingly rise due to the anticipated growth of the 'baby boomer' age group, as well as the growth of refractive surgery. Numerous studies have reported not only a loss in quality of life but also a loss in work-related performance due to the visual detriment caused by dry-eye syndrome (DES), also known as dysfunctional tear syndrome (DTS). [1] [2] [3] Patients will present with myriad symptoms, ranging from foreign body sensation, burning, and tearing to impairment of vision.
Collaboration between researchers and clinicians has provided evidencebased recommendations for identifying and treating DES. For the most effective intervention to manage a dry-eye condition, it is imperative to accurately diagnose the underlying cause of DES. The report from the International Dry Eye Workshop (DEWS) group established the multifactorial pathophysiology of DES. 4 The treatment algorithm for DES and DTS is constructed in a stepwise fashion, with the initial treatment options including topical lubricants and allowing for environmental factors that may contribute to DES. This is well recognized and accepted by the International Task Force (ITF) Delphi Panel on Dry Eye.
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Tear supplementation is the universally prescribed initial method for treating DES. Topical lubricants have evolved to include not only demulcents but also emulsifiers, surfactants, and viscosity agents. The combination of these ingredients has resulted in expanded availability and use of numerous over-the-counter (OTC) products. It is not uncommon for patients to present for evaluation having attempted to self-medicate using OTC lubricants only to experience a progression of their symptoms. After appropriately addressing environmental factors that potentially contribute to DES, tear supplementation is essential. Although patients achieve some reduction in their symptoms, two problems prevail. First, the duration of action of most artificial tears is short, requiring frequent administration of drops. 7 Second, preservatives such as benzalkonium Tears Again Liquid Gel Drops-An Assessment
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Refractive surgery has been known to trigger DES, and this subset of patients need to be carefully managed throughout the post-operative course. Few reports have been published supporting the notion that carboxymethylcellulose is superior to hydroxypropyl methylcellulose in maintaining ocular surface health post-laser-assisted in situ keratomileusis (LASIK).
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These patients tend to be younger and desire tear substitutes that have a long duration of action and easy administration. Tears Again Liquid Gel is provided in a large bottle, rather than a tube, which allows for controlled and uniform dosing. Gels that are packaged in a tube are difficult to dose due to the uncontrolled expulsion of the product when the tube is pressed. This results in an excess amount of the product being delivered to the ocular surface that often spills out onto the peri-ocular surface and increases visual blur.
Given the unique system of preservation, longer duration of ocular hydration, and convenience of dispensing from a bottle, Tears Again
Liquid Gel has filled a void that traditional tear substitutes cannot satisfy.
Certainly This paper aimed to estimate the annual cost associated with the management of dry-eye patients by ophthalmologists in France, Germany, Italy, Spain, Sweden, and the UK from the perspective of the healthcare systems in the respective countries. Published epidemiological and healthcare resource use data attributable to dry-eye syndrome were supplemented with information obtained from interviewing ophthalmologists in the six countries. The estimated prevalence of dryeye syndrome among patients reporting to ophthalmologists was less than 0.1% in all six countries.
The total annual healthcare cost of 1,000 dry-eye syndrome sufferers managed by ophthalmologists ranged from $0.27 million (95% confidence interval [CI] $0.20, $0.38 million) in France to $1.10 million (95% CI:US $0.70, $1.50 million) in the UK. A large proportion of dry-eye patients either self-treat or are managed by their general practitioner. Hence, our analysis reflects the prevalence and costs of those patients with severe enough symptoms to warrant treatment by an ophthalmologist. Given the limitations of the available economic evidence and our data sources, dry eye syndrome does not appear to impose a direct burden to healthcare expenditure in the countries investigated. However, given that many dry-eye sufferers self-treat with over-the-counter artificial tears and other medications-data that our study did not capture-the true societal costs of dry-eye syndrome borne by both patient and government are likely to be higher. ■ This paper aimed to assess the relative burden of dry eye in daily life by comparing Short Form-36 (SF-36) responses from individuals with and without dry eye against US norms. Two hundred and ten people were assessed: 130 with non-Sjögren's keratoconjunctivitis sicca (non-SS KCS), 32 with Sjögren's syndrome (SS), and 48 control subjects. The study population data and published normative SF-36 data were compared. Dry eye severity was assessed by recruited severity (control, non-SS KCS, SS), patient selfreport (none, very mild/mild, moderate, severe/extremely severe), and clinician-report (none, mild, moderate, severe). Age-and gender-matched norms were compared with all defined severity groups.
Compared with the norms, control subjects scored higher on all SF-36 scales. Effect size (ES) ranged from 0.15 to 0.52. Non-SS KCS patients had lower role-physical (ES -0.07), bodily pain (ES -0.08), and vitality (ES -0.11) scores, indicating more dry eye impact on those areas versus the norm. All SF-36 scale scores except mental health (ES = 0.12) were lower in the SS group than the adjusted norm (ES range -0.16 to -0.99). Regardless of severity classification, mild patients consistently had lower role-physical and bodily pain scores than the norm, suggesting an impact on daily roles (ES <0.2). Patients with moderately severe disease also experienced less vitality and poorer general health. The group with severe disease scored lower than the norm across all domains (ES range -0.14 to -0.91) except role-emotional (ES 0.13) and mental health (ES 0.23). These results indicate the negative impact of dry eye on everyday life, particularly in daily activities. ■
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